Literature DB >> 21901247

Studies of genomic imbalances and the MYB-NFIB gene fusion in polymorphous low-grade adenocarcinoma of the head and neck.

Fredrik Persson1, André Fehr, Kaarina Sundelin, Bernd Schulte, Thomas Löning, Göran Stenman.   

Abstract

Polymorphous low-grade adenocarcinoma (PLGA) is a malignancy predominantly originating from the minor salivary glands. The molecular events underlying the pathogenesis of PLGA is poorly understood and no recurrent genetic aberrations have so far been identified. We used genome-wide, high-resolution aCGH analysis to explore genomic imbalances in 9 cases of PLGA. Because of the well-known morphologic similarities between PLGA and adenoid cystic carcinoma (ACC) we also analyzed all tumors for expression of the recently identified ACC-associated MYB-NFIB gene fusion. aCGH analysis revealed that the PLGA genome contains comparatively few copy number alterations (CNAs). Gains/losses of whole chromosomes or chromosome arms were more than twice as common as partial CNAs. Two cases showed gain of chromosome 8 and one case each gain of chromosome 9, loss of chromosome 22 and loss of the Y chromosome. One case showed loss of the entire 6q arm and one case an interstitial deletion of a 33-Mb segment within 6q22.1-q24.3. This region contains the MYB oncogene and the candidate tumor suppressor gene PLAGL1. RT-PCR analysis revealed that one of the 9 PLGAs expressed the ACC-associated MYB-NFIB gene fusion, illustrating the diagnostic difficulties associated with the diagnosis of these morphologically partly overlapping entities. Taken together, our findings indicate that the PLGA genome is genetically stable and contains comparatively few CNAs which is in line with the clinical observation that PLGA is a slow-growing, low-grade carcinoma with low metastatic potential.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21901247     DOI: 10.3892/ijo.2011.1190

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

1.  Human Tissue Kallikreins in Polymorphous Adenocarcinoma: A Polymerase Chain Reaction and Immunohistochemical Study.

Authors:  Jacqueline Cox; Zia Khan; Linda Jackson-Boeters; Jerrold Armstrong; Mark Darling
Journal:  Head Neck Pathol       Date:  2020-06-26

2.  Adenoid cystic carcinoma of the lacrimal gland is frequently characterized by MYB rearrangement.

Authors:  T Y Chen; M G Keeney; A V Chintakuntlawar; D L Knutson; S Kloft-Nelson; P T Greipp; J A Garrity; D R Salomao; J J Garcia
Journal:  Eye (Lond)       Date:  2017-01-13       Impact factor: 3.775

3.  SOX10 and GATA3 in Adenoid Cystic Carcinoma and Polymorphous Adenocarcinoma.

Authors:  Brian D Adkins; Ariana Geromes; Lily Y Zhang; Rebecca Chernock; Katherine Kimmelshue; James Lewis; Kim Ely
Journal:  Head Neck Pathol       Date:  2019-06-20

Review 4.  Polymorphous adenocarcinoma of the salivary glands: reappraisal and update.

Authors:  Vincent Vander Poorten; Asterios Triantafyllou; Alena Skálová; Göran Stenman; Justin A Bishop; Esther Hauben; Jennifer L Hunt; Henrik Hellquist; Simon Feys; Remco De Bree; Antti A Mäkitie; Miquel Quer; Primož Strojan; Orlando Guntinas-Lichius; Alessandra Rinaldo; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-05-14       Impact factor: 2.503

Review 5.  Adenoid cystic carcinoma: emerging role of translocations and gene fusions.

Authors:  Piotr T Wysocki; Evgeny Izumchenko; Juliet Meir; Patrick K Ha; David Sidransky; Mariana Brait
Journal:  Oncotarget       Date:  2016-10-04

Review 6.  Polymorphous low-grade adenocarcinoma: an analysis of epidemiological studies and hints for pathologists.

Authors:  Vera Cavalcanti de Araujo; Fabricio Passador-Santos; Cecilia Turssi; Andresa Borges Soares; Ney Soares de Araujo
Journal:  Diagn Pathol       Date:  2013-01-15       Impact factor: 2.644

Review 7.  Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials.

Authors:  Patrick M Dillon; Samhita Chakraborty; Christopher A Moskaluk; Prashant J Joshi; Christopher Y Thomas
Journal:  Head Neck       Date:  2015-06-16       Impact factor: 3.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.